Free tool
FAERS Monitor: Risperdal Consta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021346 or its brand name (Risperdal Consta, Risperidone). Reports on generic versions are filed under their own applications.
Reports
75,399
Serious
55,531
74% of reports
Hospitalization
26,510
Death reported
6,676
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- gynaecomastia10,050
- off label use6,177
- drug ineffective5,775
- weight increased4,872
- drug interaction3,355
- abnormal weight gain3,128
- product use in unapproved indication3,031
- emotional disorder3,005
- condition aggravated2,577
- somnolence2,450
- toxicity to various agents2,312
- extrapyramidal disorder2,244
- anxiety2,080
- psychotic disorder2,039
- emotional distress2,037
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 541 |
| 2005 | 678 |
| 2006 | 935 |
| 2007 | 851 |
| 2008 | 1,012 |
| 2009 | 1,662 |
| 2010 | 1,654 |
| 2011 | 2,063 |
| 2012 | 2,326 |
| 2013 | 1,886 |
| 2014 | 2,264 |
| 2015 | 7,746 |
| 2016 | 6,152 |
| 2017 | 7,820 |
| 2018 | 5,097 |
| 2019 | 5,327 |
| 2020 | 4,534 |
| 2021 | 4,078 |
| 2022 | 4,181 |
| 2023 | 3,896 |
| 2024 | 3,917 |
| 2025 | 3,858 |
| 2026 | 2,920 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,978,760 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| gynaecomastiaSignal | 10,050 | 133.7 | 130.7 | 895,172 |
| abnormal weight gainSignal | 3,128 | 94.2 | 90.5 | 215,576 |
| emotional disorderSignal | 3,005 | 30.0 | 28.9 | 76,182 |
| extrapyramidal disorderSignal | 2,244 | 27.6 | 26.5 | 52,392 |
| psychotic disorderSignal | 2,039 | 20.6 | 19.7 | 35,467 |
| weight increasedSignal | 4,872 | 6.2 | 6.0 | 20,918 |
| drug interactionSignal | 3,355 | 6.0 | 5.8 | 13,799 |
| emotional distressSignal | 2,037 | 4.8 | 4.6 | 5,973 |
| toxicity to various agentsSignal | 2,312 | 3.9 | 3.7 | 4,876 |
| product use in unapproved indicationSignal | 3,031 | 3.4 | 3.3 | 5,245 |
| somnolenceSignal | 2,450 | 3.4 | 3.3 | 4,190 |
| condition aggravatedSignal | 2,577 | 2.4 | 2.3 | 2,065 |
| anxietySignal | 2,080 | 2.0 | 2.0 | 1,119 |
| off label use | 6,177 | 2.0 | 1.9 | 3,078 |
| drug ineffective | 5,775 | 1.2 | 1.2 | 250 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.